Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 3NIH 2NETWORK 1

Study Type

Interventional 3

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 200Neoplasms 116Breast Neoplasms 112Colorectal Neoplasms 97Ovarian Neoplasms 78Prostatic Neoplasms 75Neoplasm Metastasis 74Lung Neoplasms 66Multiple Myeloma 64Squamous Cell Carcinoma of Head and Neck 49Pancreatic Neoplasms 48Endometrial Neoplasms 48Recurrence 46Stomach Neoplasms 39Carcinoma, Renal Cell 39Small Cell Lung Carcinoma 38Melanoma 38Leukemia, Lymphocytic, Chronic, B-Cell 38Leukemia, Myeloid, Acute 34Lymphoma, Non-Hodgkin 30Urinary Bladder Neoplasms 29Parkinson Disease 4, Autosomal Dominant Lewy Body 29Triple Negative Breast Neoplasms 28Head and Neck Neoplasms 26Carcinoma, Hepatocellular 26Lymphoma, Large B-Cell, Diffuse 25Lymphoma, Follicular 25Esophageal Neoplasms 24Advanced Solid Tumors 24Lymphoma 23

Interventions

fludarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Autoimmune Diseases × 30 days × Clear all
NCT07039916 2026-05-22

Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

Immunovant Sciences GmbH

Phase 3 Recruiting
231 enrolled

Autoimmune Diseases, Myasthenia Gravis

NCT06359041 2026-05-18

RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

Cabaletta Bio

Phase 1/2 Active not recruiting
12 enrolled

Autoimmune Diseases, Myasthenia Gravis

NCT06193889 2026-05-15

KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

Kyverna Therapeutics

Phase 2/3 Recruiting
66 enrolled

Autoimmune Diseases, Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡